NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Normal Saline
Biological: PfSPZ Vaccine
Drug: artemether 20mg/lumefantrine 120mg (AL)

First Posted Date: 2018-04-27

Last Posted Date: 2021-08-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 478

Registration Number: NCT03510481

Locations: 🇲🇱
Malaria Research and Training Center, Bamako, Mali

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

Phase 1

Withdrawn

Conditions: HIV Infections

Interventions: Biological: Placebo
Biological: DNA CON-S env
Biological: IHV01

First Posted Date: 2018-04-23

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT03505060

Locations: 🇺🇸
Bridge HIV CRS, San Francisco, California, United States

Tolerance by Engaging Antigen During Cellular Homeostasis

Phase 1

Active, not recruiting

Conditions: Renal Transplantation
Renal Transplant Recipient
Kidney Transplantation

Interventions: Biological: Donor-derived Mesenchymal Stromal Cells
Drug: alemtuzumab
Drug: belatacept
Drug: sirolimus
Drug: mycophenolate mofetil
Drug: mycophenolate acid
Drug: prednisone

First Posted Date: 2018-04-20

Last Posted Date: 2024-01-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT03504241

Locations: 🇺🇸
Duke University Health System, Durham, North Carolina, United States

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

Phase 1

Active, not recruiting

Conditions: HIV Infections

Interventions: Drug: Oral Cabotegravir (CAB)
Drug: Oral Rilpivirine (RPV)
Drug: Long-Acting Injectable Rilpivirine (RPV LA)
Drug: Long-Acting Injectable Cabotegravir (CAB LA)
Drug: Combination Antiretroviral Therapy (cART)

First Posted Date: 2018-04-13

Last Posted Date: 2024-05-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 168

Registration Number: NCT03497676

Locations: 🇺🇸
Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States
🇺🇬
MU-JHU Care Limited CRS, Kampala, Uganda
🇹🇭
Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand

and more 15 locations

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

Phase 1

Terminated

Conditions: Malaria

Interventions: Drug: DM1157
Other: Placebo

First Posted Date: 2018-04-06

Last Posted Date: 2021-07-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT03490162

Locations: 🇺🇸
Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit, Durham, North Carolina, United States

2-5 Intermittent Caloric Restriction in HIV

Not Applicable

Terminated

Conditions: Human Immunodeficiency Virus
Metabolic Syndrome

Interventions: Other: Standard of Care
Behavioral: Intermittent fasting

First Posted Date: 2018-04-05

Last Posted Date: 2022-10-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 35

Registration Number: NCT03489109

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

Phase 1

Completed

Conditions: Healthy Adult Immune Responses to Vaccine

Interventions: Biological: VRC-EBOMAB092-00-AB (MAb114)

First Posted Date: 2018-03-27

Last Posted Date: 2020-10-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 19

Registration Number: NCT03478891

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

cAd3-Marburg Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Marburg Virus Disease

Interventions: Biological: cAd3-Marburg vaccine

First Posted Date: 2018-03-23

Last Posted Date: 2022-08-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT03475056

Locations: 🇺🇸
WRAIR Clinical Trials Center,, Silver Spring, Maryland, United States

H5N1 With or Without Topical Aldara in Healthy Adults

Phase 1

Completed

Conditions: Avian Influenza
Influenza Immunisation

Interventions: Drug: Imiquimod
Other: Aqueous Cream B.P.
Biological: Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04

First Posted Date: 2018-03-21

Last Posted Date: 2020-02-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT03472976

Locations: 🇺🇸
Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infection
Antiviral Prophylaxis

Interventions: Other: Placebo
Biological: SeVRSV Vaccine

First Posted Date: 2018-03-21

Last Posted Date: 2019-03-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 21

Registration Number: NCT03473002

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy